Interaction Checker

Interacciones de Sorafenib

Sorafenib (Nexavar) tiene 210 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 38; moderadas: 172; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (38)

  • Aprepitantinhibidor de CYP3A4Grave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • AxitinibGrave

    Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see Adverse Reactions (6.1) ] . (etiqueta de Axitinib, Advertencias y precauciones)

  • Bosentáninductor de CYP3A4Grave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • CarboplatinoGrave

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (etiqueta de Sorafenib, Contraindicaciones)

  • CenobamatoanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • CisplatinoGrave

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • ClobazambenzodiazepinaGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • EfavirenzantirretroviralGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • GemcitabinaantimetabolitoGrave

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • GriseofulvinaantifúngicoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Grave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • NeomicinaaminoglucósidoGrave

    Avoid concomitant use of NEXAVAR with neomycin. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • NevirapinaantirretroviralGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • PaclitaxelGrave

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (etiqueta de Sorafenib, Contraindicaciones)

  • PrimidonaanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • RifabutinaantibióticoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Grave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoGrave

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

Interacciones moderadas (172)

  • AcebutololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • AdenosinaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • AlfuzosinaalfabloqueanteModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • AliskirenoantihipertensivoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Amitriptilinaantidepresivo tricíclicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Amlodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Anagrelidafármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • AsenapinaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • AtenololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Atenolol y clortalidonabetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Azilsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Azitromicinaantibiótico macrólidoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Benazeprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • BetaxololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • BisoprololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Candesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Captoprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • CarvedilolbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • CiprofloxacinofluoroquinolonaModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • CitalopramISRSModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Claritromicinaantibiótico macrólidoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Clonidinaagonista alfa-adrenérgicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • CloroquinaantipalúdicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Clorotiazidadiurético tiazídicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • ClorpromazinaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • ClozapinaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Deutetrabenazinainhibidor de VMAT2Moderada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Digoxinaglucósido digitálicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Diltiazembloqueador de los canales de calcioModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Dinitrato de isosorbida e hidralazinanitratoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • DisopiramidaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • DofetilidaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • DoxazosinaalfabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • DronedaronaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Droperidolantagonista de la dopaminaModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Enalaprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Enalapril e hidroclorotiazidainhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Enalaprilatoinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Eritromicinaantibiótico macrólidoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • EscitalopramISRSModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • EsmololbetabloqueanteModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Espironolactonaantagonista de la aldosteronaModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Felodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • FenoxibenzaminaalfabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • FingolimodinmunosupresorModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • FlecainidaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Fluconazolantifúngico azólicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • FluoxetinaISRSModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Fosinoprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Furosemidadiurético de asaModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Granisetrónfármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Guanfacinaagonista alfa-adrenérgicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • HaloperidolantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • HidralazinavasodilatadorModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Hidroxicloroquinafármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • HidroxizinaantihistamínicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • IbutilidaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • IloperidonaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Irbesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Ketoconazolantifúngico azólicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • LabetalolbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • LevofloxacinofluoroquinolonaModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Levotiroxinahormona tiroideaModerada

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Lidocaínaanestésico localModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Lidocaína y prilocaínaanestésico localModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Liotironinahormona tiroideaModerada

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Lisinoprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Lofexidinaagonista alfa-adrenérgicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Loperamidafármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Losartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • MecamilaminaantihipertensivoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • MetadonaopioideModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • MetildopaantihipertensivoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Metimazolfármaco antitiroideoModerada

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Metolazonadiurético tiazídicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • MetoprololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • MexiletinaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • MinoxidilvasodilatadorModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Moexiprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • MoxifloxacinofluoroquinolonaModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • NadololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • NebivololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Nicardipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Nilotinibfármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • NitroprusiatovasodilatadorModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • OfloxacinofluoroquinolonaModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Olmesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Ondansetrónfármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PaliperidonaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Pentamidinafármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Perindoprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PimavanserinaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PimozidaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PindololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Pitolisantfármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PrazosinaalfabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • ProcainamidaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PrometazinaantihistamínicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Prometazina y codeínaopioideModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Prometazina y dextrometorfanoantihistamínicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PropafenonaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Propiltiouracilofármaco antitiroideoModerada

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • PropranololbetabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • QuetiapinaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Quinaprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Quinapril e hidroclorotiazidainhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • QuinidinaantiarrítmicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • QuininaantipalúdicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Ramiprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • RisperidonaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Sacubitrilo y valsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • SolifenacinaanticolinérgicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • SotalolbetabloqueanteModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Telmisartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • TerazosinaalfabloqueanteModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Teriparatidahormona tiroideaModerada

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Tetrabenazinainhibidor de VMAT2Moderada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • TioridazinaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Tizanidinarelajante muscularModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • TolterodinaanticolinérgicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Torasemidadiurético de asaModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Toremifenomodulador selectivo de los receptores de estrógenosModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • TramadolopioideModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Tramadol y paracetamolopioideModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Trandolaprilinhibidor de la ECAModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • TrazodonaantidepresivoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Valbenazinainhibidor de VMAT2Moderada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Valsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Vardenafiloinhibidor de la PDE5Moderada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • VenlafaxinaIRSNModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Verapamilobloqueador de los canales de calcioModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • Voriconazolantifúngico azólicoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • WarfarinaanticoagulanteModerada

    Increased Risk of Bleeding with Concomitant Use of Warfarin Infrequent bleeding or elevations in the International Normalized Ratio (INR) have been reported in some patients taking warfarin while on NEXAVAR. (etiqueta de Sorafenib, Advertencias y precauciones)

  • ZiprasidonaantipsicóticoModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

Compruebe Sorafenib frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.